Solventum has appointed former Zimmer Biomet executive Rachel Ellingson as chief strategy and corporate development officer.

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Solventum Corporation (SOLV – Research Report) today and set a price target of ...

Solventum (NYSE:SOLV – Get Free Report) is one of 238 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals?We will compare Solventum to ...

Shares of NYSE:SOLV opened at $77.96 on Wednesday. The business has a 50 day moving average price of $73.65 and a 200 day moving average price of $70.55. Solventum has a twelve month low of $47.16 ...

Diversified healthcare company Solventum (NYSE:SOLV) reported fourth-quarter 2024 earnings on Thursday, Feb. 27, that topped analysts' consensus estimates. Adjusted EPS for the quarter came in at ...

Solventum Corp., 3M’s medtech spinoff, has sold its purification and filtration business to Massachussetts-based Thermo Fisher Scientific for approximately $4.1 billion. Solventum Corp. (NYSE ...

Mizuho raised the firm’s price target on Solventum (SOLV) to $82 from $70 and keeps a Neutral rating on the shares following the Q4 report. The firm cites the company’s potential for ...

It’s been almost a year since Solventum spun off as a separate business from 3M. Now, Solventum is orchestrating a spinoff of its own. On Tuesday, Solventum announced that it has lined up a deal ...

Shares of Solventum rose Tuesday after the company agreed to sell its filtration and purification business to medical device maker Thermo Fisher Scientific for $4.1 billion. Solventum Chief ...

Solventum Co. (NYSE:SOLV – Get Free Report) has been assigned an average rating of “Hold” from the eleven brokerages that are currently covering the company, MarketBeat.com reports.